SONA.CX Quote, Financials, Valuation and Earnings

Biocure Technology has a net margin of -- compared to Sona Nanotech, Inc.'s net margin of --. Sona Nanotech, Inc.'s return on equity of -528.15% beat Biocure Technology's return on equity of --.

Sona Nanotech, Inc. has a consensus price target of --, signalling upside risk potential of 374.58%. On the other hand Biocure Technology has an analysts' consensus of -- which suggests that it could fall by --. Given that Sona Nanotech, Inc. has higher upside potential than Biocure Technology, analysts believe Sona Nanotech, Inc. is more attractive than Biocure Technology.

Sona Nanotech, Inc. has a beta of 0.761, which suggesting that the stock is 23.857% less volatile than S&P 500. In comparison Biocure Technology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Sona Nanotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biocure Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sona Nanotech, Inc. pays -- of its earnings as a dividend. Biocure Technology pays out -- of its earnings as a dividend.

Sona Nanotech, Inc. quarterly revenues are --, which are larger than Biocure Technology quarterly revenues of --. Sona Nanotech, Inc.'s net income of -$658.7K is higher than Biocure Technology's net income of --. Notably, Sona Nanotech, Inc.'s price-to-earnings ratio is -- while Biocure Technology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sona Nanotech, Inc. is -- versus -- for Biocure Technology. Usually stocks with elevated PS ratios are considered overvalued.

Microbix Biosystems, Inc. has a net margin of -- compared to Sona Nanotech, Inc.'s net margin of -27.67%. Sona Nanotech, Inc.'s return on equity of -528.15% beat Microbix Biosystems, Inc.'s return on equity of -14.86%.

Sona Nanotech, Inc. has a consensus price target of --, signalling upside risk potential of 374.58%. On the other hand Microbix Biosystems, Inc. has an analysts' consensus of $0.50 which suggests that it could grow by 122.22%. Given that Sona Nanotech, Inc. has higher upside potential than Microbix Biosystems, Inc., analysts believe Sona Nanotech, Inc. is more attractive than Microbix Biosystems, Inc..

Sona Nanotech, Inc. has a beta of 0.761, which suggesting that the stock is 23.857% less volatile than S&P 500. In comparison Microbix Biosystems, Inc. has a beta of 0.579, suggesting its less volatile than the S&P 500 by 42.148%.

Sona Nanotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Microbix Biosystems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sona Nanotech, Inc. pays -- of its earnings as a dividend. Microbix Biosystems, Inc. pays out -- of its earnings as a dividend.

Sona Nanotech, Inc. quarterly revenues are --, which are smaller than Microbix Biosystems, Inc. quarterly revenues of $4.2M. Sona Nanotech, Inc.'s net income of -$658.7K is higher than Microbix Biosystems, Inc.'s net income of -$1.2M. Notably, Sona Nanotech, Inc.'s price-to-earnings ratio is -- while Microbix Biosystems, Inc.'s PE ratio is 25.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sona Nanotech, Inc. is -- versus 1.80x for Microbix Biosystems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Resverlogix Corp. has a net margin of -- compared to Sona Nanotech, Inc.'s net margin of --. Sona Nanotech, Inc.'s return on equity of -528.15% beat Resverlogix Corp.'s return on equity of --.

Sona Nanotech, Inc. has a consensus price target of --, signalling upside risk potential of 374.58%. On the other hand Resverlogix Corp. has an analysts' consensus of -- which suggests that it could grow by 4661.91%. Given that Resverlogix Corp. has higher upside potential than Sona Nanotech, Inc., analysts believe Resverlogix Corp. is more attractive than Sona Nanotech, Inc..

Sona Nanotech, Inc. has a beta of 0.761, which suggesting that the stock is 23.857% less volatile than S&P 500. In comparison Resverlogix Corp. has a beta of 1.058, suggesting its more volatile than the S&P 500 by 5.792%.

Sona Nanotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Resverlogix Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sona Nanotech, Inc. pays -- of its earnings as a dividend. Resverlogix Corp. pays out -- of its earnings as a dividend.

Sona Nanotech, Inc. quarterly revenues are --, which are smaller than Resverlogix Corp. quarterly revenues of --. Sona Nanotech, Inc.'s net income of -$658.7K is higher than Resverlogix Corp.'s net income of -$1.3M. Notably, Sona Nanotech, Inc.'s price-to-earnings ratio is -- while Resverlogix Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sona Nanotech, Inc. is -- versus -- for Resverlogix Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Theratechnologies, Inc. has a net margin of -- compared to Sona Nanotech, Inc.'s net margin of -25.17%. Sona Nanotech, Inc.'s return on equity of -528.15% beat Theratechnologies, Inc.'s return on equity of --.

Sona Nanotech, Inc. has a consensus price target of --, signalling upside risk potential of 374.58%. On the other hand Theratechnologies, Inc. has an analysts' consensus of $7.25 which suggests that it could grow by 62.19%. Given that Sona Nanotech, Inc. has higher upside potential than Theratechnologies, Inc., analysts believe Sona Nanotech, Inc. is more attractive than Theratechnologies, Inc..

Sona Nanotech, Inc. has a beta of 0.761, which suggesting that the stock is 23.857% less volatile than S&P 500. In comparison Theratechnologies, Inc. has a beta of 0.396, suggesting its less volatile than the S&P 500 by 60.409%.

Sona Nanotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theratechnologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sona Nanotech, Inc. pays -- of its earnings as a dividend. Theratechnologies, Inc. pays out -- of its earnings as a dividend.

Sona Nanotech, Inc. quarterly revenues are --, which are smaller than Theratechnologies, Inc. quarterly revenues of $24.9M. Sona Nanotech, Inc.'s net income of -$658.7K is higher than Theratechnologies, Inc.'s net income of -$6.3M. Notably, Sona Nanotech, Inc.'s price-to-earnings ratio is -- while Theratechnologies, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sona Nanotech, Inc. is -- versus 1.86x for Theratechnologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.